SCHEMBL2566348

SCHEMBL2566348

Cc1ncn(Cc2ccccc2)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.53
CYP11B2 P19099 3/20 0.53
TNF P01375 1/20 0.53
TSHR P16473 2/20 0.49
KDM4E B2RXH2 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
GAA P10253 1/20 0.47
PKM P14618 1/20 0.47
HTT P42858 1/20 0.47
ADORA2B P29275 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
ADORA2A P29274 1/20 0.45
PI4KA P42356 1/20 0.45
PI4K2B Q8TCG2 1/20 0.45
PI4K2A Q9BTU6 1/20 0.45
PI4KB Q9UBF8 1/20 0.45
NOTUM Q6P988 1/20 0.45
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21199068 0.81 ADORA2A (0.54) CYP11B1CYP11B2TNFTSHRKDM4E
SCHEMBL8830129 0.81 CYP11B1 (0.50) CYP11B1CYP11B2TNFTSHRKDM4E
SCHEMBL20438539 0.81 CYP11B1 (0.46) CYP11B1CYP11B2TNFTSHRLMNA
SCHEMBL11211782 0.79 CYP11B1 (0.47) CYP11B1CYP11B2TNFTSHRLMNA
SCHEMBL7034716 0.79 MEN1 (0.51) CYP11B1CYP11B2LMNASMN1; SMN2GAA
Hydrochloric Acid SCHEMBL11295371 0.79 CYP11B1 (0.47) CYP11B1CYP11B2TNFTSHRKDM4E
SCHEMBL8830053 0.79 CYP11B1 (0.47) CYP11B1CYP11B2TNFTSHRKDM4E
Hydrochloric Acid SCHEMBL8830023 0.79 CYP11B1 (0.47) CYP11B1CYP11B2TNFTSHRKDM4E
SCHEMBL11207135 0.78 LMNA (0.50) CYP11B1CYP11B2TNFTSHRKDM4E
SCHEMBL4958156 0.78 PKM (0.69) CYP11B1CYP11B2TNFTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022266768-A1 IRON-BASED COMPLEXES FOR USE IN THE CATALYSIS OF HYDROSILYLATION REACTIONS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2022-12-29 WO disclosed
EP-3774795-B1 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS UNIV MASARYKOVA (CZ) 2022-03-16 EP disclosed
WO-2019185631-A1 4—(1H— IMIDAZOL— 5— YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS MASARYKOVA UNIVERZITA (CZ) 2019-10-03 WO disclosed
US-10278973-B2 Hydroxyl purine compounds and use thereof Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-05-07 US disclosed
US-20180140607-A1 HYDROXYL PURINE COMPOUNDS AND USE THEREOF Guangdong Raynovent Biotech Co., Ltd. (CN) 2018-05-24 US disclosed
EP-3299371-A1 HYDROXYL PURINE COMPOUNDS AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-28 EP disclosed
US-8193224-B2 Medicinal composition for prevention or treatment of parasitic protozoan infection FUJIFILM CORPORATION (JP) 2012-06-05 US disclosed
EP-1818334-B1 ANTI-TRYPANOSOMIASIS AGENT IHARA MASATAKA (JP) 2011-11-02 EP disclosed
US-7795285-B2 Anti-trypanosomiasis agent FUJIFILM CORPORATION (JP) 2010-09-14 US disclosed
US-20100113789-A1 MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF PARASITIC PROTOZOAN INFECTION Ihara, Masataka (JP) 2010-05-06 US disclosed
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds GILEAD SCIENCES, INC. 2008-03-27 US disclosed
US-20080045574-A1 thiazolidin-4-one derivatives used as antiprotozoa agents, or for the treatment of trypanosomiasis JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2008-02-21 US disclosed
EP-1818334-A1 ANTI-TRYPANOSOMIASIS AGENT Japan Science and Technology Agency (JP) 2007-08-15 EP disclosed
EP-1800682-A1 MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF PARASITIC PROTOZOAN INFECTION Japan Science and Technology Agency (JP) 2007-06-27 EP disclosed
US-20070027147-A1 Biarylurea derivatives MSD K.K. (JP) 2007-02-01 US disclosed
US-20070027147-A1 Biarylurea derivatives MSD K.K. (JP) 2007-02-01 US disclosed
CN-1684680-A Imidazole alkaloid of lepidium meyenii and application thereof PURE WORLD BOTAN INC (US) 2005-10-19 CN disclosed
US-5670526-A ANTIINFLAMMATORY AGENT, IMMUNOSUPPRESSANT OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-09-23 US disclosed
US-4612324-A Imidazole derivatives for treating joint diseases and Wilson's disease HOFFMANN-LA ROCHE INC. (US) 1986-09-16 US disclosed
EP-0118787-A1 Alpha-amino-2-imidazole propionic-acid derivatives F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045574-A1 thiazolidin-4-one derivatives used as antiprotozoa agents, or for the treatment of trypanosomiasis TXN2, SQOR, TXNRD2 CYP11B1 256/4885CYP11B2 288/4885TNF 4276/4885
US-20180140607-A1 HYDROXYL PURINE COMPOUNDS AND USE THEREOF PNP, PDE7A, PDE2A CYP11B1 172/4885CYP11B2 78/4885TNF 103/4885
US-10278973-B2 Hydroxyl purine compounds and use thereof PNP, PDE7A, PDE2A CYP11B1 172/4885CYP11B2 78/4885TNF 103/4885
US-20100113789-A1 MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF PARASITIC PROTOZOAN INFECTION MRM1, NR1I3, RORA CYP11B1 47/4885CYP11B2 80/4885TNF 3674/4885
US-20070027147-A1 Biarylurea derivatives CDK6, CDK4, CCNI CYP11B1 516/4885CYP11B2 781/4885TNF 3420/4885
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds TYMP, PNP, PIKFYVE CYP11B1 3563/4885CYP11B2 3942/4885TNF 4815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.